Multiple Sclerosis, Relapsing-Remitting: all 615 studies

Page 2 of 7. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.

• Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With OcrevusCompletedNCT03562975Results posted
• Melatonin in Patients With Multiple Sclerosis (MS).CompletedNCT03498131Early Phase 1Results posted
• A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)TerminatedNCT03387046Phase 2Results posted
• Maximizing Outcome of Multiple Sclerosis TransplantationTerminatedNCT03342638Phase 3Results posted
• COMparison Between All immunoTherapies for Multiple Sclerosis.CompletedNCT03193866Results posted
• Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to OcrelizumabCompletedNCT03157830Results posted
• Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)TerminatedNCT03126760Phase 4Results posted
• A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2CompletedNCT03093324Phase 3Results posted
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)TerminatedNCT03085810Phase 3Results posted
• Light Therapy as Treatment for Fatigue in Multiple SclerosisCompletedNCT03060759Not applicableResults posted
• Intranasal Insulin for Improving Cognitive Function in Multiple SclerosisCompletedNCT02988401Phase 1/2Results posted
• A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple SclerosisTerminatedNCT02975349Phase 2Results posted
• Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis PatientsCompletedNCT02939079Phase 2/3Results posted
• Efficacy and Safety of Daclizumab in Participants With RRMS Switching From NatalizumabTerminatedNCT02881567Phase 3Results posted
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)CompletedNCT02861014Phase 3Results posted
• Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)CompletedNCT02720107Phase 4Results posted
• Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple SclerosisCompletedNCT02687919Not applicableResults posted
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)CompletedNCT02637856Phase 3Results posted
• A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1CompletedNCT02634307Phase 3Results posted
• Plegridy Satisfaction Study in ParticipantsCompletedNCT02587065Phase 4Results posted
• Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02555215Phase 3Results posted
• A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple SclerosisCompletedNCT02545868Phase 3Results posted
• Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).CompletedNCT02525874Phase 3Results posted
• Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®CompletedNCT02499900Phase 4Results posted
• Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMSCompletedNCT02410200Phase 2Results posted
• Fingolimod Effect on Cytokine and Chemokine LevelsCompletedNCT02373098Phase 4Results posted
• Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsTerminatedNCT02342704Phase 4Results posted
• ACTH for Fatigue in Multiple Sclerosis PatientsCompletedNCT02315872Phase 3Results posted
• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT02283853Phase 3Results posted
• Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)CompletedNCT02258217Not applicableResults posted
• Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409CompletedNCT02255656Phase 4Results posted
• Pilot Study to Assess Dimethyl Fumarate Related GI Symptom MitigationTerminatedNCT02217982Phase 4Results posted
• Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In GermanyCompletedNCT02125604Phase 4Results posted
• Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT02090413Phase 4Results posted
• A Study of Rebif® in Subjects With Relapsing Multiple SclerosisCompletedNCT02064816Phase 4Results posted
• Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple SclerosisCompletedNCT02040298Phase 2Results posted
• A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT02038049Phase 2Results posted
• Rebif® Rebidose® Versus Rebiject II® Ease-of-UseCompletedNCT02019550Phase 4Results posted
• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)TerminatedNCT01963611Phase 2Results posted
• Measurement of Relaxin Peptide in Multiple Sclerosis (MS)CompletedNCT01909492Results posted
• Safety and Tolerability of Glatiramer AcetateCompletedNCT01874145Phase 3Results posted
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019TerminatedNCT01797965Phase 3Results posted
• A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ DeviceCompletedNCT01791244Phase 4Results posted
• Raltegravir (Isentress) Pilot Study in Relapsing Multiple SclerosisCompletedNCT01767701Phase 2Results posted
• The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT01707992Phase 3Results posted
• A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®CompletedNCT01705236Phase 4Results posted
• Pharmacokinetics of Vitamin D in Multiple Sclerosis and in HealthCompletedNCT01667796Not applicableResults posted
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxoneTerminatedNCT01633112Phase 3Results posted
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.CompletedNCT01623596Phase 4Results posted
• An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01578785Phase 3Results posted
• Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)CompletedNCT01534182Phase 4Results posted
• Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to FingolimodTerminatedNCT01499667Phase 3Results posted
• Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying TherapyCompletedNCT01498887Phase 4Results posted
• Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01497262Phase 3Results posted
• Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple SclerosisTerminatedNCT01490840Phase 4Results posted
• Vitamin D Supplementation in Multiple SclerosisCompletedNCT01490502Phase 3Results posted
• Efficacy and Safety of GTR in Comparison to Copaxone®CompletedNCT01489254Phase 3Results posted
• An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisCompletedNCT01462318Phase 3Results posted
• Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple SclerosisCompletedNCT01457924Phase 2Results posted
• Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With DepressionTerminatedNCT01436643Phase 4Results posted
• A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01433250Phase 2Results posted
• Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01416155Phase 2Results posted
• Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear CellsCompletedNCT01414634Phase 1/2Results posted
• Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)CompletedNCT01405820Phase 2Results posted
• Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple SclerosisCompletedNCT01395316Phase 4Results posted
• Fingolimod Versus Interferon Beta 1b in Cognitive SymptomsCompletedNCT01333501Phase 4Results posted
• Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy ChangeCompletedNCT01317004Phase 4Results posted
• Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® TreatmentCompletedNCT01285401Phase 2Results posted
• Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01226745Phase 2Results posted
• Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis PatientsCompletedNCT01225289Phase 4Results posted
• Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis PatientsCompletedNCT01201343Phase 4Results posted
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01185821Phase 2Results posted
• Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT01167426Phase 3Results posted
• BG00012 Phase 2 Combination Study in Participants With Multiple SclerosisCompletedNCT01156311Phase 2Results posted
• Natalizumab De-escalation With Interferon Beta-1bCompletedNCT01144052Phase 4Results posted
• A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After MitoxantroneCompletedNCT01142466Phase 4Results posted
• Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]TerminatedNCT01134627Phase 2Results posted
• A Cooperative Clinical Study of Abatacept in Multiple SclerosisCompletedNCT01116427Phase 2Results posted
• ATX-MS-1467 in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01097668Phase 1Results posted
• Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01093326Phase 2Results posted
• Treatment Interruption of NatalizumabCompletedNCT01071083Phase 2Results posted
• A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to PlaceboCompletedNCT01067521Phase 3Results posted
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01064401Phase 3Results posted
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisTerminatedNCT01058005Phase 3Results posted
• POC-MD MRI-based Trial in Relapsing-remitting Multiple SclerCompletedNCT01051817Phase 2Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT01051349Phase 2Results posted
• Patient Research Cohort: Rapidly Evolving Multiple SclerosisCompletedNCT01044576Results posted
• Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01006265Phase 2Results posted
• Safety of New Formulation of Glatiramer AcetateCompletedNCT00947752Phase 3Results posted
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabCompletedNCT00930553Phase 3Results posted
• A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT00882999Phase 2Results posted
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00879658Phase 2Results posted
• A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT00871780Phase 4Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00870740Phase 2Results posted
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)CompletedNCT00835770Phase 3Results posted
• Rehabilitation Study in MS PatientsTerminatedNCT00780455Phase 4Results posted
• An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the DiseaseTerminatedNCT00745615Phase 2Results posted
• A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00676715Phase 2Results posted
• Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00662649Phase 3Results posted
• CLARITY Extension StudyCompletedNCT00641537Phase 3Results posted

← Multiple Sclerosis, Relapsing-Remitting overview